With M&A Deal, Click Therapeutics' Digital Prospects in Metabolic Disease Get Better - MedCity News
Briefly

Digital therapeutics developer Click Therapeutics acquired Better Therapeutics to enhance its presence in cardiometabolic disorders with the FDA-authorized AspyreRx diabetes app.
This acquisition provides Click a springboard for drug and digital treatment pairings, expanding its successful hybrid model with existing programs like Clickotine and Rejoyn.
Read at MedCity News
[
|
]